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ABSTRACT  
Objective: To develop a new cationic nanoemulsion (NE) for ophthalmic delivery of indomethacin (IND) to improve the permeability and retention 
time of formulations, thereby improving the drug's ocular bioavailability.  
Methods: Based on the solubility profile of indomethacin in various solvents, captex 8000 was selected as oil phase, span 20 as a surfactant and tween 
20 as co-surfactant to construct pseudo ternary phase diagrams and nanoemulsion region was recognized. Sonication was used as the method of NE 
preparation. Optimization was done using 32 factorial designs by considering the oil and the ratio of surfactant to co-surfactant (Smix) quantities as 
independent variables and evaluated for different physicochemical properties. Ex vivo transcorneal permeability was studied using bovine cornea, the In 
vivo drug pharmacokinetics of optimized NE and marketed formulation were assessed in rabbit aqueous humor and also in plasma.  
Results: The mean globule size, zeta potential, viscosity, refractive index, pH, surface tension and the osmolarity values for the prepared 
indomethacin nanoemulsions (IND-NEs) were found between 129.8±1.1 to 191.4±1.6 nm, +13.20±4.6 to+23.45±4.82, 15.3±0.1 to 32.7±0.0 mPas, 
1.346±0.007 to 1.386±0.005, 5.5±0.4 to 6.9±0.9, 32.0±2.6 to 52.3±3.4 mN/m and 303-395 mOsm/l respectively and all these values found to be 
falling under the recommended values for ophthalmic use. From the In vitro release studies, it was found that the IND-NEs exhibited sustained drug 
release with 67.91±2.01 to 95.90±1.93 % drug release at 24h when compared to the drug solution which showed 99.81±5.21 % drug release within 
2h. The Ex vivo drug permeation through the corneal membrane at 4h from the optimized NE and drug solution was found to be 524±1.5 µg/cm2 
and 175±2.6 µg/cm2 respectively. Further, the optimized NE was found to be nonirritant with the lowest ocular irritation potential (Iirr) of 1 
towards the rabbit's eyes. The area under the drug concentration vs. time curve for 24h (AUC (0–24h)) for optimized NE and the marketed formulation 
was found to be 1514.99 ng/ml/h and 974.14 ng/ml/h in aqueous humour; 2266.83 ng/ml/h and 778.15 ng/ml/h in plasma respectively. 
Conclusion: Due to its improved corneal absorption and prolonged drug release along with less systemic absorption, the optimized NE offers an 
effective postoperative treatment with increased ocular bioavailability and improved patient compliance with a decrease in the number of 
installations per day and a decrease or disappearance of systemic side effects of IND.  
Keywords: Cationic nanoemulsion, Ophthalmic drug delivery, Permeability, Bioavailability, Optimization, Indomethacin 32 factorial designs, 
Sonication, Captex 8000, Aqueous humor, Ocular irritation 
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INTRODUCTION 
Postoperative pain and irritation symptoms are relatively common 
during the first hours after surgery [1], which is associated with a 
breakdown of the blood-aqueous barrier as a result of surgical 
trauma induced prostaglandin production. In general, 
corticosteroids are prescribed to control postoperative 
inflammation; however, they found increasing intraocular pressure, 
delaying in corneal epithelial and stromal wound healing, and more 
susceptible to microbial infections. Hence, the use of non-steroidal 
anti-inflammatory drugs becomes an alternative treatment [2].  
The topical route is preferred to administer ophthalmic dosage 
forms due to benefits like the ease of application, targetability, 
reduced side effects and also cost-effectiveness [3]. Most of the 
conventional ophthalmic dosage forms are in an aqueous solution of 
water-soluble drugs and either as an ointment or suspension of 
water-insoluble drugs. Frequent administration is required for 
aqueous solutions due to poor ocular bioavailability and drug loss 
through the nasolacrimal drainage which may lead to extremely 
unwanted pharmacokinetics and systemic toxicity suggesting the 
necessity of new alternatives to ocular drug delivery. Coming to the 
water-insoluble drugs, ointments suffer from poor patient 
acceptance because of blurred vision and matted eyelids, and 
suspensions lead to particle irritation, poor bioavailability, and 
changes in polymorphism and particle size upon storage [4]. 
Besides, the complex structure of the human eye can limit the 
bioavailability of ocular drugs. Due to poor ocular bioavailability, 
higher concentrations of the conventional form of analgesic used 
during surgery may result in ocular and systemic side effects. 
NEs are advantageous for topical ocular drug delivery due to their 
ability to solubilize drugs in a large quantity, enhance absorption, 
achieve sustained drug release and target the affected area of the eye 
[5]. NEs are kinetically stable colloidal dispersions with droplet sizes 
on the order of 100 nm. Because of their small size, they are optically 
transparent in appearance, possess high surface area per unit volume, 
have excellent stability and variable viscosity [6]. Apart from their 
excellent physicochemical properties and stability, the NE systems for 
ocular delivery are easy to fabricate and characterize. NEs can deliver 
both hydrophilic and lipophilic drug moieties both to the anterior and 
posterior segments of the eye, in a safe and reproducible manner with 
improved patient compliance [7]. Because of the increased 
bioavailability and reduced drug toxicity, the NEs may serve as the 
potential delivery systems for ocular administration [8]. 
The objective of the present study was to develop a new cationic NE for 
ophthalmic delivery of indomethacin IND with improved permeability 
and retention time thereby improving drug’s ocular bioavailability. 
MATERIALS AND METHODS  
Materials 
IND was received as a gift sample from Sreeji Pharma International, 
Vadodara, India. The materials like captex 100, captex 200, captex 355, 
captex 8000, were generously donated by Abitec Corporation, Mumbai, 
India. Capryol 90, capmul MCM C8, capmul MCM L8, labrafil M 1994, 
labrafil M 2125 and acconon E were gifted from Gettefosse, Saint-Priest 
Cedex, France. Tween 20, tween 40, tween 80, polyethyleneglycol (PEG) 
200, propylene glycol (PG), span 20 were purchased from Himedia 
Laboratories, Mumbai, India. Water was double-distilled and used 
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throughout the study. High-performance liquid chromatography (HPLC) 
grade solvents (methanol and acetonitrile) were used for drug analysis. 
All other chemicals used in the present study were of analytical reagent 
grade and were purchased from S D Fine Chemicals, India. The In vivo 
studies were conducted in healthy adult New Zealand albino rabbits free 
from visible ocular abnormalities, weighing about 2–3 kg of either sex 
and were procured from Jeeva Life Sciences, Hyderabad. The study 
protocol (IAEC/49/UCPSc/KU/2018) was approved by the institutional 
animal ethical committee, University College of Pharmaceutical Sciences, 
Kakatiya University, Warangal, Telangana, India. 
Quantitative analysis of IND 
Stock solution and working sample preparation 
100 mg of IND was dissolved in 50 ml of HPLC grade methanol and 
the final volume was adjusted up to 100 ml to prepare a stock 
solution of 1000μg/ml concentration. For the calibration curve, the 
stock solution was again diluted with the help of diluents to get final 
working concentrations of 10-500ng/ml.  
Quantitative analysis conditions 
The quantitative analysis of IND was performed using ultrafast 
liquid chromatography (UFLC, Shimadzu L220) containing LC-20AD 
isocratic pump, SPD-20A UV/Vis detector, and rheodyne injector 
was used. The UFLC process was carried out on a C8 column (100 
mm x 4.6 mm and the particle size of 5 µm). The mobile phase 
comprised of 0.5% v/v O-Phosphoric acid: methanol: acetonitrile in 
the ratio of 40:20:40, respectively. The flow rate was set at 1.0 
ml/min and about 20 µl of sample solutions were injected into the 
UFLC in triplicate using Hamilton microsyringe and measured at a 
wavelength of 270 nm [9].  
The chromatographic data analysis was done by using the LC solution 
software. A standard plot of concentration of the drug (ng/ml) vs. peak 
area was plotted. The linearity of the calibration curve was established 
by the correlation coefficient value obtained from the graph. 
Solubility study 
The solubility of IND in quite a few solvents was determined by adding 
an excess amount of drug in 2 ml of the solvent (captex 100, captex 200, 
captex 355, captex 8000, capryol 90, capmul MCM C8, capmul MCM L8, 
labrafil M 1994, labrafil M 2125, acconol E, tween 20, tween 40, tween 
80, PEG 200, PG and span 20) individually in 5 ml stopper vials and 
mixed with a vortex mixer for 10 min. To attain an equilibrium, the vials 
were stored at 25 ˚C in an isothermal shaker for 72h. The samples were 
centrifuged at 3000 rpm for 30 min. The supernatant was collected and 
filtered using a 0.22 mm membrane filter. The concentration of IND in 
the filtrate was analyzed by the UFLC [10]. 
Ternary phase diagrams 
The most stable emulsion systems usually consist of blends of two or 
more emulsifiers, one portion having lipophilic tendencies, the other 
hydrophilic [11]. To find out the suitable blend that can better 
solubilize IND and can form emulsions of nano-size, the aqueous 
titration method was used to make pseudo ternary systems and the 
pseudo ternary diagrams were plotted using CHEMIX School 
software [12]. Surfactant and co-surfactants were mixed in altered 
weight proportions of 1:1, 1:2, 1:3and 2:1 and were designated as 
Smix ratios. Then, altered weight ratios of oil and Smix (1:9, 2:8, 3:7, 
4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) were prepared [13, 14] and the 
aqueous phase was added dropwise to each altered weight ratios of 
oil and Smix with continuous stirring till solution converts turbid. 
For every phase diagram, the systems were inspected for the 
transparency in appearance visually.  
Optimization by 32 factorial designs  
A 2-factor, 3-level factorial design using Design-Expert (Version 12, 
Stat-Ease Inc., Minneapolis, MN) software was applied to optimize 
the formulation compositions. The selected independent variables 
and experimental responses were the percentage of oil (X1) and 
Smix (X2); and mean globule size (Y1) and percentage drug release 
(Y2), respectively. Table 1 illustrates the selected factor levels from 
the phase diagram for the factorial design. To recognize the 
significant effect of independent variables on the experimental 
responses, response surface analyses were carried out [15]. 
Preparation of IND-NEs 
IND-NEs were prepared by the ultrasonic emulsification method by 
using probe sonicator. A total of 9 NEs were prepared in which the oil 
phase contained drug, oil and Smix, and aqueous phase contained PG 
dissolved in water. IND (0.1% w/v) was added by vortexing into the 
optimized quantity of oil and Smix until clear solutions were obtained. 
The hot aqueous phase (50˚C) was dropwise added to the oil phase 
with continuous stirring at 250 rpm using a magnetic stirrer to 
produce a primary emulsion, which is then sonicated at an amplitude 
of 50, pulse 5s on and 3s off for 10 min to get nanoemulsion [16]. 
Physicochemical evaluation of IND-NEs  
Particle size measurements 
The mean globule size of the IND-NEs was determined by using 
photon correlation spectroscopy (Zeta seizer, ZS Nano, Malvern 
Instruments Ltd., UK), which analyzes the fluctuations in the light 
scattering of the particle. Light scattering was checked at 25˚C at a 
90˚ angle. While zeta potential measurements were performed using 
a disposable zeta cuvette. For each sample, the mean diameter and 
zeta potential±standard deviation of three determinations was 
calculated applying multimodal analysis [17].  
Viscosity determination 
The viscosity of the IND-NEs was determined using Brookfield 
viscometer (Model DV-II+Pro Brookfield Ltd, Middleboro, MA) using 
a C50-1 spindle at 25±0.5 ˚C in triplicate [18, 19]. 
Refractive index and pH measurement 
The refractive index of the IND-NEs was measured by using an 
Abbes refractometer by placing one drop of formulation on the slide 
(Nirmal International, New Delhi, India) at 25±0.5˚C in triplicate. 
The pH of the NEs was measured by a digital pH meter (DPH 504) in 
triplicate at 25˚C [20]. 
Surface tension measurements 
Surface tension measurements were carried out by the Du Nouy ring 
method using an electronic Tensiometer (model-K100, KRÜSS, 
Germany) [21]. The force referred to the wetted length acting on a 
ring as a result of the tension of the withdrawn liquid lamella when 
moving the ring from one phase to another is measured in this 
method and the mathematical formula involved is as followed. 
σ = F/l. cosθ ------------ (1) 
Osmolarity determination 
Osmolarity is an important parameter by which one can predict the 
irritability of the formulation. It was calculated using the following 
equation [22].  






∗  particle number ∗ 1000 -- (2) 
Stability testing 
To evaluate the stability, IND-NEs were subjected to thermodynamic 
stability testing, which comprises of a heating-cooling cycle, freeze-
thaw cycle and centrifugation. The nanoemulsions were examined 
for stability at temperatures 45 ˚C (heating) and 4 ˚C (cooling) 
subsequently for not less than 48h. These alternating cycles of 
heating and cooling were repeated at least six times. Selected 
nanoemulsions were kept in a deep freezer at-20 ˚C for about 48h. 
After that, the nanoemulsions were removed from the freezer and 
kept at room temperature (25 ˚C) to return to the original form. This 
step of freeze-thaw was repeated 2-3 times. After freeze-thaw cycle 
nanoemulsions were subjected to centrifugation where they were 
centrifuged at 3,500 rpm for 30 min, and checked for any phase 
separation, change in mean globule size and drug content [23].  
Drug content 
A small fixed volume of IND-NEs was taken and diluted with 
methanol. Then the samples were analyzed by using UFLC and the 
concentrations were calculated from the calibration curve [24, 25]. 
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In vitro release study 
In vitro release of IND-NEs was evaluated and compared with that of 
control by the diffusion technique using Franz diffusion cells and 
dialysis membrane. 1 ml of simulated tear fluid (STF) with a dose 
equivalent amount of IND was served as control. The setup was kept 
under continuous stirring with a Teflon-coated magnetic bar on a 
magnetic stirrer at 100 rpm, maintaining a constant temperature of 
32±0.5 ˚C. 1 ml sample was withdrawn at every predetermined time 
points i.e. 0.5, 1, 2, 4, 6, 8, 12 and 24h. The same amount of fresh STF 
was replaced into the receiver compartment. Withdrawn samples 
were estimated for the drug content by UFLC 270 nm [26]. 
Surface morphology 
Transmission electron microscopy (TEM) was used to study the 
morphology of the optimized NE observed under different 
magnifications by following the standard protocol practicing at RUSKA 
Labs, PV Narshimha Rao Telangana Veterinary University, Telangana, 
India. For the TEM study, a drop of the NE was appropriately diluted 
with water and applied on a carbon-coated grid, and then treated with 
a drop of 2% phosphotungstic acid and kept aside for the 30s. The 
carbon-coated grid was then dried and taken onto a slide and 
observed under the microscope. A combination of bright field imaging 
at cumulative magnification and diffraction modes was used to 
evaluate the size and morphology of the NE [27]. 
Ex vivo corneal permeation studies 
The Ex vivo permeation studies were carried out using bovine corneas, 
which is a reliable method for the prediction of drug transport across 
the corneal membrane. The eyeballs of bovine were obtained from a 
slaughterhouse and transported to the laboratory in normal saline 
maintained at 4 ˚C. The corneas were carefully removed along with a 
5–6 mm of surrounding sclera and washed with cold saline. The 
washed corneas were kept in cold, freshly prepared STF of pH 7.4. The 
study was carried out by using Franz-diffusion cells in such a way that 
the epidermal side was in intimate contact with the formulation in the 
donor compartment. The receptor compartment was filled with STF at 
34±0.5 ˚C. The receptor medium was stirred at 50 rpm. The samples 
were withdrawn at different time intervals and replaced with an equal 
volume of STF. The permeation study was carried out for 4h, and 
samples were analyzed by UFLC at 270 nm. Results were expressed as 
the mean of three experiments±SD. The amount of drug permeated 
per unit area through the excised cornea (µg/cm2) versus time (h) 
was plotted and the permeation parameters of drug in the different 
formulae were calculated [28-30].  
In vivo studies 
Ocular irritation studies 
Ocular irritancy of optimized NE was studied on healthy adult New 
Zealand albino rabbits free from visible ocular abnormalities, 
weighing about 2–3 kg of either sex. 30 μl of test formulation 
previously sterilized using 0.2 µm syringe filter was instilled into the 
right eye of each rabbit (n=3) and observed for ocular irritation 
reactions like redness, conjunctival chemosis and discharge for 24h 
keeping the untreated eye as a control. The scoring was given from 0 
to 4 for the absence to highest observed abnormality and an on the 
whole Iirr was calculated by summing up the total scores for each 
category. The Iirr of more than 4 was considered the presence of 
clinically significant irritation [31]. 
Drug pharmacokinetics in plasma 
6 Rabbits were divided into 2 groups of three animals each. Gruop1 
received control (Indocollyre 0.1% ophthalmic solution, Bosch and 
Lomb) and Group 2 received test (optimized NE) samples of 30 µl 
each. 200 µl of blood samples were collected into heparinized tubes 
at 0.5, 0.75, 1, 2, 4, 8, 12 and 24h time-points through the marginal 
vein. After collection, samples were immediately stored at 
temperature (-20 ˚C) until the analysis [32, 33]. 
Drug pharmacokinetics in aqueous humour 
To study and compare the pharmacokinetics of optimized NE in 
aqueous humour with that of marketed formulation, 24 animals 
(three animals corresponding to each sampling point) were used 
and the time points include 0.5, 0.75, 1, 2, 4, 8, 12 and 24h. Each 
animal was placed in an individual restraining box, 30 µl of the test 
sample (optimized NE) and control (marketed product) were 
topically applied on to the right eye and left eye, respectively. 100 µl 
of aqueous humor was collected from three animals at each time 
point by inserting 22 G needle of an insulin syringe into the anterior 
segment of the eye through the cornea without causing any injury to 
iris and lens. Before collecting the samples, a combination of 35 
mg/kg ketamine hydrochloride and 5 mg/kg xylazine was used to 
anesthetize the rabbits by injecting intramuscularly [34]. After 
collection, samples were immediately stored at temperature (-20 ˚C) 
until the analysis. 
Analysis of aqueous humour and blood samples 
Different calibration standards ranging from 50–500 ng/ml were 
prepared by adding 10 µl of known working solution of drug to 90 µl 
of drug-free rabbit aqueous humor/blood. All samples were 
vortexed to ensure complete mixing and 20 µl was used for UFLC 
analysis. The aqueous humor/blood samples collected were mixed 
with 200 µl of acetonitrile, vortexed and centrifuged for 30 min at 
3000rpm. 20 µl of the organic phase was used for UFLC analysis [35, 
36]. 
RESULTS AND DISCUSSION  
Calibration curve 
The calibration curve was plotted between peak area and 
concentration (ng/ml) as shown in fig. 1. The linearity was seen at a 
concentration range of 2.5 to 100 ng/ml with a regression coefficient 
(R2) value of 0.998. The retention time was found to be 5.4±0.34 min 
as shown in fig. 2. 
  
 
Fig. 1: Calibration curve 
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Fig. 2: UFLC chromatogram of IND (RT-5.4) 
 
Solubility study 
The solubility of IND in various oils, surfactants and co-surfactants 
were depicted in fig. 3. Among oils, captex 8000 showed very good 
solubility. Therefore, it was selected as the oil phase. Among 
surfactants and co-surfactants, IND had the highest solubility in span 
20 and tween 20; hence they were selected as surfactant and co-
surfactant respectively for the phase study. 
  
 
Fig. 3: Indomethacin solubility in various solvents, *error bars represent standard deviations of three replicates 
 
 
Fig. 4: Ternary phase diagrams for Smix ratios (1:1, 1:2, 1:3, 2:1 and 3:1 from right to left) 
 
Table 1: 32 factorial design showing independent and dependent variables 
Formulation code  Coded value  Actual value  
X1  X2  X1  X2  
IND-NE1  1  1  15  60  
IND-NE2  -1  0  12.5  55  
IND-NE3  -1  1  12.5  60  
IND-NE4  1   0  15  55  
IND-NE5   0  -1  10  50  
IND-NE6  -1  -1  12.5  50  
IND-NE7  0  1  10  60  
IND-NE8   0   0  10  55  
IND-NE9   1  -1  15  50  
Independent variables  Levels  
Low (-1)  Medium (0)  High (1)  
X1-amount of oil (%w/w) 







Dependent variables  Y1-Mean droplet size (nm) 
Y2-Cumulative drug release (%)  
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Table 2: Formulation composition 
Formulation code   Oil (%w/v)  Surfactant mix (% w/v)  1% Propylene glycol (%w/v)  Aqueous phase (%v/v)  
IND-NE1  15  60  2.5  22.5  
IND-NE2  10  55  2.5  32.5  
IND-NE3  10  60  2.5  27.5  
IND-NE4  15  55  2.5  27.5  
IND-NE5  12.5  50  2.5  35  
IND-NE6  10  50  2.5  37.5  
IND-NE7  12.5  60  2.5  25  
IND-NE8  12.5  55  2.5  30  
IND-NE9  15  50  2.5  32.5  
*IND and cetalkonium chloride content remained constant at 0.1 %w/v and 0.01 %w/v respectively in all formulations  
 
Physicochemical evaluation 
The IND-NEs found suitable for ocular delivery with satisfactory 
physicochemical characteristics and the complete profile was 
depicted in table 3. The mean globule size for all of the IND-NEs was 
found less than 200 nm ranging from 129.8±1.1 to 191.4±1.6 nm 
confirming the successful formation of NE. This small size could be 
related to the penetration of the co-surfactant molecules into the 
surfactant film. This would decrease the fluidity and surface 
viscosity of the interfacial film, lower the radius of curvature of the 
droplets and thus form transparent systems [37]. The zeta potential 
of IND-NEs ranged from+13.20±4.6 to+23.45±4.82. The positive 
charge helps to improve the retention time and also helps in 
improving corneal absorption due to electrostatic interactions with 
the corneal membrane [38]. The viscosity ranged from 15.3±0.1 to 
32.7±0.0 mPas. In general, 15-150 mPas of viscosity is 
recommended as this low viscosity will ensure the transparency and 
hence no visual impairment upon eye drop instillation into the eyes 
without compromising the prolonged retention time [39]. Refractive 
index measurements tell about the possibility of discomfort to the 
patient after the administration of eye drops. It is recommended that 
eye drops should have refractive index values near to that of tear 
fluid i.e., 1.340 to 1.360 or not higher than 1.476 and for the 
prepared IND-NEs, the refractive index values ranged from 
1.346±0.007 to 1.386±0.005 which are within the recommended 
value. The ideal pH for maximum comfort to the eye is of 7.2 ± 0.2. 
However, the human eye can tolerate a pH of 3.5 to 8.5. The pH 
values of the IND-NEs were found in the range of 5.5±0.4 to 6.9±0.9 
and hence provide better comfort to the eyes [40]. The surface 
tension of the IND-NEs was found to be in the range of 32.0±2.6 to 
52.3±3.4 mN/m ensuring the good spreadability of the IND-NEs over 
the corneal membrane. The osmolarity values of IND-NEs were 
found within the range of 303-395 mOsm/l falling under the 
recommended values [41]. 
Stability 
IND-NEs remained clear with no phase separation or drug precipitation, 
indicating their excellent physical stability. All the formulations were 
found to be consistent concerning their mean globule size, drug content, 
phase separation and transparency during the stability study. The 
physical data comparing their mean globule size and drug content before 
and after stability studies were given in table 4. 
In vitro release studies 
To facilitate comparison between release behaviors of different NE 
formulae, the In vitro drug release profiles of the IND-NEs were 
graphically illustrated in fig. 5. The release results of NE revealed 
that the prepared formulations were found to exhibit sustained 
release with 67.91±2.01 to 95.90±1.93 % drug release at 24h in 
comparison to control which showed 99.81±5.21 % drug release 
within 2 h. The variation in drug release between IND-NEs can be 
emphasized from the formulation composition variables and the 
droplet size of the formulations. 
  
Table 3: Physical data of different evaluation parameters 
Formulation code  MGS (nm)  PDI  ZP (mV)  Viscosity  
(mPas)  




IND-NE1  152.8±1.9  0.070±0.000  +14.1±5.25  15.3±0.1  6.9±0.9  1.346±0.007  52.3±3.4  382  
IND-NE2  183.8±1.1  0.209±0.110  +17.8±5.86  16.8±0.1  6.7±0.2  1.347±0.002  49.5±2.5 337  
IND-NE3  180.1±0.8  0.253±0.012  +15.3±4.83  20.7±0.2  6.8±0.6  1.368±0.002  46.4±3.7  324  
IND-NE4  157.7±1.5  0.031±0.021  +14.7±3.51  18.4±0.1  6.9±0.5  1.348±0.005 44.1±1.9  352  
IND-NE5  137.3±1.6  0.272±0.040  +22±4.09  22.3±0.5  6.8±0.7  1.346±0.001  41.5±1.8  368  
IND-NE6  191.4±1.6  0.512±0.001  +13.2±4.6  24.4±0.2  5.9±0.6  1.369±0.001  43.1±4.0  372  
IND-NE7  116.4±1.5  0.318±0.003  +22.6±5.45  20.1±0.0  6.8±0.3  1.340±0.001  39±2.5  379  
IND-NE8  128.9±1.1  0.237±0.011  +23±4.82  26.0±0.1  5.5±0.4  1.368±0.002  32±2.6  381  
IND-NE9  176.5±2.0  0.318±0.005  +18.4±3.84  32.7±0.0  6.9±0.8  1.386±0.005  37.9±3.5  355  
*Values are expressed as mean±SD (n=3), MGS-mean globule size, PDI-poly dispersity index, ZP-zeta potential, RI-refractive index. 
 
Table 4: Physical evaluation data of before and after stability studies 
Formulation code  Mean globule size (nm)   Drug content (%)  
Freshly prepared  After stability studies  Freshly prepared  After stability studies  
NF1  152.8±1.9  150.12±0.44  99.52±0.12  99.47±0.54  
NF2  183.8±1.1  185.42±0.13  96.51±1.06  95.07±1.65  
NF3  180.1±0.8  182.71±0.42   97.35±1.83  96.52±2.20  
NF4  157.7±1.5  159.14±0.56  95.72±1.27  94.18±1.32  
NF5  137.3±1.6  138.18±0.54  99.87±2.52  98.73±2.03  
NF6  191.4±1.6  194.62±0.34  98.34±1.05  98.25±1.36  
NF7  116.4±1.5  118.24±0.55  96.96±1.99  96.15±2.42  
NF8  128.9±1.1  129.13±0.81  98.92±1.92  97.87±1.25  
NF9  176.5±2.0  179.02±0.65  98.46±1.24  98.39±1.86  
*Values are expressed as mean±SD (n=3) 
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Fig. 5: In vitro drug release profiles, *error bars represent standard deviations of three replicates 
 
Optimization by response surface analysis 
The experimental data were fitted into the quadratic model and the 
predicted R² of mean globule size and % drug release were found to 
be 0.9505 and 0.8177 respectively and were in reasonable 
agreement with the adjusted R² of 0.9852 and 0.9599 respectively; 
i.e. the difference is less than 0.2. Adequate precision measures the 
signal to noise ratio. A ratio greater than 4 is desirable. Here, the 
ratio of 27.662 for mean globule size and 17.793 for % drug release 
indicated an adequate signal. The model found significant with the F-
value of 107.49 for mean globule size and 39.33 for % drug release. 
P-values less than 0.0500 indicate that the model terms are 
significant. The model terms A, B, AB, A², B² were found significant 
for both mean globule size and % drug release.  
The final equation in terms of coded factors for mean globule size 
(Y1) and % drug release (Y2): 
Y1=125.811-11.2833 X1-9.28333 X2-3.15 X1 X2+46.0833 X1 2+2.58333 X2 2 -- (3) 
Y2=94.1444+5.37167 X1+3.81167 X2+0.36 X1X2-14.4817 X1 2-1.56167 X2 2 ---
----- (4) 
From the response surface analysis, it was evident that the oil and 
Smix compositions showed a significant effect on mean globule size 
and % drug release. The effects were represented as 3D surface 
plots in fig. 6. It is prominently noticed that an increase in oil content 
provided a decrease in globule size to some extent and a further 
increase in oil content lead to a slight increase in globule size and an 
opposite effect was seen for percentage drug release. However, by 
increasing the Smix content, the globule size decreased and the 
percentage drug release increased. Zainol S et al. (2012) reported an 
increase in the mean globule size when the oil composition of 
levodopa lipid emulsions was increased [42]. Reddy et al. (2011) 
developed felodipine nanoemulsions and reported that the mean 
globule size reduced from 231.8 to 162.7 nm by increasing the 
surfactant concentration from 1 to 1.5% [43]. In the present study, 
the drug release was found to be affected by their droplet size. The 
decrease in droplet size increased the total number of oil globules 
and a subsequent increase in their surface area, which led to an 
increase in drug release. Thus the formulation IND-NE7 with the 
medium oil and high Smix was found to have the lowest mean 
globule size and significantly high drug release; hence it was chosen 
as the optimized formulation and was subjected to further study. 
Similar results were reported by Yadav et al. (2020) where low oil 
and high surfactant levels of emulsion composition for ezetimibe 




Fig. 6: 3D Response surface plots showing the effect of oil and Smix content on (a) mean globule size (nm), (b) Drug release (%) 
 
Surface morphology 
The droplets in the IND-NE7 appeared dark, and spherical with size 
more or less similar and less than 100 nm. The image can be seen in 
fig. 7.  
Ex vivo corneal permeation studies using bovine corneas 
The drug permeated through the corneal membrane at 4 h from 
the IND-NE7 and drug solution was found to be 524±1.5 µg/cm2 
and 175±2.6 µg/cm2, respectively. The results for the drug solution 
Ajmeera et al. 
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were found quite the opposite to the in vitro drug diffusion rate. 
This can be explained by the structural complexity of the corneal 
membrane that opposes the aqueous solution because of the outer 
lipophilic layer. In the case of IND-NE7, the nano-sized globules 
can be easily infiltrated by endocytosis and the permeation 
enhancing the ability of the formulation ingredients will cause 
temporary changes in the tight junctions of the corneal membrane 
that enhances the permeation by transcellular pathway. Similar 
results were reported by Sayed et al. (2017), where the high in 
vitro drug diffusion rate from the drug solution was reversed in 
case of corneal permeation and the nanovesicles showed more 
corneal permeation compared to the drug solution due to the 
above said reasons [45]. The graphical representation of the 
comparative ex vivo drug permeation profiles of test and control 
were shown in fig. 8 and the drug permeation parameters were 
depicted in table 5. 
 
 
Fig. 7: TEM image of optimized formulation (IND-NE7) 
 
 
Fig. 8: Ex vivo drug permeation profiles, *error bars represent standard deviations of three replicates 
 
Table 5: Ex vivo drug permeation parameters 
Parameter  Control  Test formulation  
Flux (µg/cm2/h)  55.732  166.878  
Papp(cm/s)  1.54×10-5  4.63×10-5  
Corneal hydration (%)  72.2±0.13  66.5±0.24  
*Values are expressed as mean±SD (n=3) 
 
Ocular irritation test 
IND-NE7 found nonirritant with a minimal score of 1 in the Draize eye 
test. The rabbits showed slight redness of the conjunctiva, which 
disappeared completely within 15 min, but no lachrymation or 
chemosis was observed throughout the study indicating the optimized 
formulation is nonirritant and could be tolerated by the rabbit eye.  
In vivo pharmacokinetics 
The graphical representation of the comparative In vivo drug 
concentration profiles of test and control was shown in fig. 9 and the 
pharmacokinetic parameters were depicted in table 6. The AUC (0–24h) 
for IND-NE7 and the marketed formulation was found to be 1514.99 
ng/ml/h and 974.14 ng/ml/h in aqueous humour; 2266.83 ng/ml/h 
and 778.15 ng/ml/h in plasma respectively. The plasma levels and 
aqueous humor levels of IND confirmed that 1.55 fold increased 
bioavailability in the aqueous humour and 2.91 fold decreased 
bioavailability in the systemic circulation of IND-NE7 when 
compared to the marketed IND ophthalmic solution. The reason for 
improved corneal absorption can be explained by the small globule 
size, improved retention time due to viscosity and the positive 
charge on the droplets imparted by cetalkonium chloride involved in 
the electrostatic interaction with the negatively charged corneal 
membrane and that lead to improved residence time on cornea [46]. 
Ban J et al. (2017) reported similar results for dexamethasone lipid 
nanoparticles, which showed a 2.7 fold increased bioavailability in 
aqueous humour compared to the drug solution due to the nano-size 
and positive charge on the nanoparticles [47]. 
Ajmeera et al. 




Fig. 9: In vivo drug concentration profile, *error bars represent standard deviations of three replicates 
 
Table 6: Pharmacokinetic parameters in the rabbit model 
Parameter  Aqueous humor  Plasma  
Control  Test formulation  Control  Test formulation  
AUC(0-24h) (ng/ml/h)  974.14  1514.99  2266.83  778.15  
Tmax (h)  1  1.5  1  1.5  
Cmax (ng/ml)  189.15  250.45  270.22  150.73  
*Values are expressed as mean±SD (n=3) 
 
Table 7: One sample t-test for IND-NE7 vs. control formulation 
One sample t-test   INDO-NE7  
Aqueous humour Plasma  
Actual mean  57.56  155.5  
Number of values  8  8  
t, df  t=2.362, df=8  t=3.793, df=7  
P value  0.0458  0.0068  
Significant (alpha=<0.05)  Yes  Yes  
95% confidence interval  1.373 to 113.7  58.57 to 252.4 
R2 0.4109 0.6727 
 
The obtained results were found to be statistically significant when 
analyzed by a one-sample t-test using GraphPad Prism software 
version, 8.0.2 and were depicted in table 7. 
CONCLUSION 
Novel cationic IND-NEs for topical ophthalmic delivery were 
prepared successfully using captex 8000, span 20, tween 20, PG and 
glycerol. Almost all prepared IND-NEs showed acceptable 
physicochemical properties and thermodynamic stability. However, 
IND-NE7 showed the highest drug release among all and was 
nonirritant to the rabbits’ eyes. The drug release rate from NEs was 
found to be dependent on the oil and Smix content used in NE 
preparation. IND-NE7 improved IND permeation across the bovine 
cornea and showed improved corneal absorption with prolonged 
drug release compared to marketed eye drops. Thus, IND-NE7 offers 
an effective postoperative treatment with increased ocular 
bioavailability and improved patient compliance with a decrease in 
the number of installations per day and a decrease or disappearance 
of systemic side effects of IND.  
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